|
KMID : 0923620200200010008
|
|
Immune Network
2020 Volume.20 No. 1 p.8 ~ p.8
|
|
|
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
|
|
Kim Kyung-Hwan
Kim Chang-Gon
Shin Eui-Cheol
|
|
|
Abstract
|
|
|
|
Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or in combination with other anti-cancer therapies, and its indications are expanding. However, many patients do not benefit from anti-PD-1/PD-L1 therapy due to primary and/or acquired resistance, which is a major obstacle to broadening the clinical applicability of anti-PD-1/PD-L1 therapy. In addition, hyperprogressive disease, an acceleration of tumor growth following anti-PD-1/PD-L1 therapy, has been proposed as a new response pattern associated with deleterious prognosis. Anti-PD-1/PD-L1 therapy can also cause a unique pattern of adverse events termed immune-related adverse events, sometimes leading to treatment discontinuation and fatal outcomes. Investigations have been carried out to predict and monitor treatment outcomes using peripheral blood as an alternative to tissue biopsy. This review summarizes recent studies utilizing peripheral blood immune cells to predict various outcomes in cancer patients treated with anti-PD-1/PD-L1 therapy.
|
|
|
KEYWORD
|
|
|
Blood, Biomarkers, PD-1 receptor, Programmed cell death 1 ligand 1, Prognosis, Adverse drug event
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|